Author

M Reguiero

Institution: Cleveland Clinic

Observed institution: Cleveland Clinic

OpenAlex ID: A5029446295

DOP39 Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programme

2022 · P Higgins, J F Colombel, et al. · Journal of Crohn s and Colitis · 5

P0945 Improvement in Endoscopic Score in Patients with Moderately to Severely Active UC Treated with Risankizumab in the Phase 3 INSPIRE and COMMAND Studies

2025 · R Panaccione, B Verstockt, et al. · Journal of Crohn s and Colitis

Works count: 2

Citation count: 5

H-index: 1

I10-index: